Werewolf Therapeutics, Inc.
HOWL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,885 | $19,943 | $16,401 | $0 |
| % Growth | -90.5% | 21.6% | – | – |
| Cost of Goods Sold | $1,814 | $1,764 | $2,510 | $0 |
| Gross Profit | $71 | $18,179 | $13,891 | $0 |
| % Margin | 3.8% | 91.2% | 84.7% | – |
| R&D Expenses | $56,434 | $41,776 | $53,761 | $35,269 |
| G&A Expenses | $19,045 | $18,670 | $17,328 | $14,818 |
| SG&A Expenses | $19,045 | $18,670 | $21,501 | $14,818 |
| Sales & Mktg Exp. | $0 | $0 | $4,173 | $0 |
| Other Operating Expenses | -$1,814 | -$1,764 | -$5,315 | $0 |
| Operating Expenses | $73,665 | $58,682 | $69,947 | $50,087 |
| Operating Income | -$73,594 | -$40,503 | -$56,056 | -$50,087 |
| % Margin | -3,904.2% | -203.1% | -341.8% | – |
| Other Income/Exp. Net | $3,079 | $3,135 | $2,246 | $104 |
| Pre-Tax Income | -$70,515 | -$37,368 | -$53,810 | -$49,983 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$70,515 | -$37,368 | -$53,810 | -$49,983 |
| % Margin | -3,740.8% | -187.4% | -328.1% | – |
| EPS | -1.63 | -1.05 | -1.86 | -10.94 |
| % Growth | -55.2% | 43.5% | 83% | – |
| EPS Diluted | -1.63 | -1.05 | -1.86 | -10.94 |
| Weighted Avg Shares Out | 43,332 | 35,647 | 28,864 | 18,455 |
| Weighted Avg Shares Out Dil | 43,860 | 35,647 | 28,864 | 18,455 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,673 | $7,416 | $1,908 | $104 |
| Interest Expense | $4,656 | $3,139 | $0 | $0 |
| Depreciation & Amortization | $1,814 | $1,764 | $2,510 | $216 |
| EBITDA | -$64,045 | -$32,465 | -$51,300 | -$49,871 |
| % Margin | -3,397.6% | -162.8% | -312.8% | – |